Strides receives USFDA approval for Lidocaine Ointment

Product approval from flagship facility in Bangalore
To be launched immediately by Strides Pharma Inc. in the US markets

Bangalore, 12 December, 2018 Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Lidocaine Ointment USP 5% from the United States Food & Drug Administration (US FDA). Lidocaine Ointment is a generic version of Xylocaine® Ointment of AstraZeneca Pharmaceuticals LP.

According to IQVIA MAT data, the US market for Lidocaine Ointment USP 5% is approximately US$ 50 Mn. The product will be marketed by Strides Pharma Inc. in the US Market and will be launched immediately.

The company has 80 cumulative ANDA filings with USFDA of which 54 ANDAs have been approved as of date and 26 are pending approval.

About Lidocaine Ointment
Lidocaine Ointment contains a local anesthetic agent which is administered topically to numb and relieve pain from minor burns, skin abrasions, and other painful conditions affecting mucous membranes. Lidocaine Ointment is also used to numb the skin before certain medical procedures.

About Strides
Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is global pharmaceutical Company headquartered in Bangalore. The Company has two business verticals, viz., Regulated Markets and Emerging Markets. The Company has a global manufacturing footprint with 7 manufacturing facilities spread across three continents including 5 facilities for Regulated Markets and 2 facilities for the Emerging Markets. The Company has strong R&D infrastructure in India with global filing capabilities and a strong commercial footprint across 100 countries. Additional information is available at the Company’s website at www.strides.com

For further information, please contact:

**Strides**
Badree Komandur,
Executive Director - Finance
+91 80 6784 0747

**PR Consultancy**
Fortuna PR
K Srinivas Reddy: +91 90005 27213
srinivas@fortunapr.com

K Priya: +91 95354 25418
priya@fortunapr.com
**Investor Relations:**
Kannan. N: +91 98450 54745  
Vikesh Kumar: +91 80 6784 0827  
Sandeep Baid : +91 80 6784 0791  
Email: Sandeep.baid@strides.com

**Strides Pharma Science Limited**  
(Formerly Strides Shasun Limited)  
CIN : L24230MH1990PLC057062  
Regd. Office: 201, ‘Devavrata’, Sector - 17, Vashi, Navi Mumbai - 400 703  
Corp. Office: Strides House, Bannerghatta Road, Bangalore - 560076